PURPOSE: Conventional radiation fractionation of 1.8-2 Gy per day for early stage breast cancer requires daily treatment for 6-7 weeks. We report the 5-year results of a phase II study of intensity modulated radiation therapy (IMRT), hypofractionation, and incorporated boost that shortened treatment time to 4 weeks. METHODS AND MATERIALS: The study design was phase II with a planned accrual of 75 patients. Eligibility included patients aged≥18 years, Tis-T2, stage 0-II, and breast conservation. Photon IMRT and an incorporated boost was used, and the whole breast received 2.25 Gy per fraction for a total of 45 Gy, and the tumor bed received 2.8 Gy per fraction for a total of 56 Gy in 20 treatments over 4 weeks. Patients were followed every 6 months for 5 years. RESULTS: Seventy-five patients were treated from December 2003 to November 2005. The median follow-up was 69 months. Median age was 52 years (range, 31-81). Median tumor size was 1.4 cm (range, 0.1-3.5). Eighty percent of tumors were node negative; 93% of patients had negative margins, and 7% of patients had close (>0 and <2 mm) margins; 76% of cancers were invasive ductal type: 15% were ductal carcinoma in situ, 5% were lobular, and 4% were other histology types. Twenty-nine percent of patients 29% had grade 3 carcinoma, and 20% of patients had extensive in situ carcinoma; 11% of patients received chemotherapy, 36% received endocrine therapy, 33% received both, and 20% received neither. There were 3 instances of local recurrence for a 5-year actuarial rate of 2.7%. CONCLUSIONS: This 4-week course of hypofractionated radiation with incorporated boost was associated with excellent local control, comparable to historical results of 6-7 weeks of conventional whole-breast fractionation with sequential boost.
PURPOSE: Conventional radiation fractionation of 1.8-2 Gy per day for early stage breast cancer requires daily treatment for 6-7 weeks. We report the 5-year results of a phase II study of intensity modulated radiation therapy (IMRT), hypofractionation, and incorporated boost that shortened treatment time to 4 weeks. METHODS AND MATERIALS: The study design was phase II with a planned accrual of 75 patients. Eligibility included patients aged≥18 years, Tis-T2, stage 0-II, and breast conservation. Photon IMRT and an incorporated boost was used, and the whole breast received 2.25 Gy per fraction for a total of 45 Gy, and the tumor bed received 2.8 Gy per fraction for a total of 56 Gy in 20 treatments over 4 weeks. Patients were followed every 6 months for 5 years. RESULTS: Seventy-five patients were treated from December 2003 to November 2005. The median follow-up was 69 months. Median age was 52 years (range, 31-81). Median tumor size was 1.4 cm (range, 0.1-3.5). Eighty percent of tumors were node negative; 93% of patients had negative margins, and 7% of patients had close (>0 and <2 mm) margins; 76% of cancers were invasive ductal type: 15% were ductal carcinoma in situ, 5% were lobular, and 4% were other histology types. Twenty-nine percent of patients 29% had grade 3 carcinoma, and 20% of patients had extensive in situ carcinoma; 11% of patients received chemotherapy, 36% received endocrine therapy, 33% received both, and 20% received neither. There were 3 instances of local recurrence for a 5-year actuarial rate of 2.7%. CONCLUSIONS: This 4-week course of hypofractionated radiation with incorporated boost was associated with excellent local control, comparable to historical results of 6-7 weeks of conventional whole-breast fractionation with sequential boost.
Authors: Timothy J Whelan; Jean-Philippe Pignol; Mark N Levine; Jim A Julian; Robert MacKenzie; Sameer Parpia; Wendy Shelley; Laval Grimard; Julie Bowen; Himu Lukka; Francisco Perera; Anthony Fyles; Ken Schneider; Sunil Gulavita; Carolyn Freeman Journal: N Engl J Med Date: 2010-02-11 Impact factor: 91.245
Authors: P Romestaing; Y Lehingue; C Carrie; R Coquard; X Montbarbon; J M Ardiet; N Mamelle; J P Gérard Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Gary M Freedman; Tianyu Li; Nicos Nicolaou; Yan Chen; Charlie C-M Ma; Penny R Anderson Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-11 Impact factor: 7.038
Authors: S M Bentzen; R K Agrawal; E G A Aird; J M Barrett; P J Barrett-Lee; S M Bentzen; J M Bliss; J Brown; J A Dewar; H J Dobbs; J S Haviland; P J Hoskin; P Hopwood; P A Lawton; B J Magee; J Mills; D A L Morgan; J R Owen; S Simmons; G Sumo; M A Sydenham; K Venables; J R Yarnold Journal: Lancet Date: 2008-03-19 Impact factor: 79.321
Authors: Pierfrancesco Franco; Domenico Cante; Piera Sciacero; Giuseppe Girelli; Maria Rosa La Porta; Umberto Ricardi Journal: Breast Care (Basel) Date: 2015-02 Impact factor: 2.860
Authors: F Sedlmayer; M L Sautter-Bihl; W Budach; J Dunst; P Feyer; R Fietkau; W Haase; W Harms; C Rödel; R Souchon; F Wenz; R Sauer Journal: Strahlenther Onkol Date: 2013-03 Impact factor: 3.621
Authors: Moamen M O M Aly; Gerhard Glatting; Lennart Jahnke; Frederik Wenz; Yasser Abo-Madyan Journal: Radiat Oncol Date: 2015-07-09 Impact factor: 3.481